Dana Faber Cancer Institute — Boston, Massachusetts

Dana Faber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.

Dana Faber Cancer Institute has participated in 17 clinical trials with 2 currently active.

Therapeutic areas: Advanced Solid Tumors, Small-Cell Lung Cancer, Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Sponsors: U3 Pharma GmbH, Novartis Pharmaceuticals, Bristol-Myers Squibb.

Sponsor Feasibility Report

Trust Score: 80/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Faber Cancer Institute?

Dana Faber Cancer Institute has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Faber Cancer Institute conducted?

Dana Faber Cancer Institute has 17 clinical trials on record, with 2 currently active. Their work covers Advanced Solid Tumors, Small-Cell Lung Cancer, Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Is Dana Faber Cancer Institute accredited by Crixeo Health?

Dana Faber Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Faber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.